Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

A Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Pharmacokinetics of Stapokibart Injection in Adolescent Patients With SAR Under Background Therapy

This study is a multicenter, single-arm, open-label, phase II study to evaluate the safety, pharmacokinetics, and immunogenicity of Stapokibart injection in Adolescent Patients with SAR.

Inclusion Criteria:

• Voluntarily sign the Informed Consent Form.
• Age ≥ 12 years old and <18 years old, weight ≥ 40 kg.
• With a diagnosis of SAR, with or without allergic conjunctivitis, and the SAR duration was ≥ 2 years.

Exclusion Criteria:

• Not enough washing-out period for previous therapies.
• With other poorly controlled serious diseases or chronic conditions.
• With any conditions that are not suitable for participation in this study by investigators.